- Home
- PRPL vs HLVX Comparison
PRPL vs HLVX Comparison
Compare PRPL & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- HLVX
- Stock Information
- Founded
- PRPL 2010
- HLVX 2020
- Country
- PRPL United States
- HLVX United States
- Employees
- PRPL N/A
- HLVX N/A
- Industry
- PRPL Home Furnishings
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- PRPL Consumer Discretionary
- HLVX Health Care
- Exchange
- PRPL Nasdaq
- HLVX Nasdaq
- Market Cap
- PRPL 90.3M
- HLVX 95.1M
- IPO Year
- PRPL N/A
- HLVX 2022
- Fundamental
- Price
- PRPL $1.09
- HLVX $1.92
- Analyst Decision
- PRPL Buy
- HLVX Hold
- Analyst Count
- PRPL 3
- HLVX 5
- Target Price
- PRPL $1.70
- HLVX $2.33
- AVG Volume (30 Days)
- PRPL 532.7K
- HLVX 177.0K
- Earning Date
- PRPL 03-11-2025
- HLVX 03-19-2025
- Dividend Yield
- PRPL N/A
- HLVX N/A
- EPS Growth
- PRPL N/A
- HLVX N/A
- EPS
- PRPL N/A
- HLVX N/A
- Revenue
- PRPL $504,838,000.00
- HLVX N/A
- Revenue This Year
- PRPL N/A
- HLVX N/A
- Revenue Next Year
- PRPL $1.89
- HLVX N/A
- P/E Ratio
- PRPL N/A
- HLVX N/A
- Revenue Growth
- PRPL N/A
- HLVX N/A
- 52 Week Low
- PRPL $0.75
- HLVX $1.55
- 52 Week High
- PRPL $2.33
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- PRPL 52.20
- HLVX 44.27
- Support Level
- PRPL $0.98
- HLVX $1.90
- Resistance Level
- PRPL $1.29
- HLVX $2.00
- Average True Range (ATR)
- PRPL 0.11
- HLVX 0.06
- MACD
- PRPL -0.00
- HLVX -0.01
- Stochastic Oscillator
- PRPL 38.80
- HLVX 24.10
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.